Viruses cause infectious diseases such as influenza, cold, HIV/AIDS, warts, Ebola, smallpox, and several other diseases. These viruses attack normal living cells and multiply by reproducing their own type. They can be treated with antiretroviral drugs.
When compared to antibacterial drugs, the number of antiviral drugs available is rather small because of the complexity in acquiring selective toxicity against viruses.
Several proteins and enzymes are found only in these viruses and can be targeted for antiviral drugs. A number of virus-specific replication phases have been identified that are targets for a variety of antiviral drugs. Various classes of antiretroviral agents have been categorized as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), fusion inhibitors (FIs), protease inhibitors (PIs), chemokine receptor antagonists (CCR5), and integrase inhibitors (INSTIs).
BioVision is pleased to provide ~34 antiviral agents for customers’ research.
Figure. Drug discovery for antiviral agents.
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.
BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.